Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CMP 001

Drug Profile

CMP 001

Alternative Names: ARB 1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-QbG10; Immunodrug™ CYT003-QbG10; QbG10; Virus-like particle-based cancer vaccine - Checkmate; VLP-based cancer vaccine - Checkmate

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytos Biotechnology
  • Developer Arbutus Biopharma; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Cytos Biotechnology; Genocea Biosciences; Pfizer; University of Pittsburgh
  • Class Allergy immunotherapies; Antiallergics; Cancer vaccines; Oligonucleotides; Virus-like particle vaccines
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Solid tumours; Squamous cell cancer
  • Phase I Colorectal cancer; Non-small cell lung cancer
  • Preclinical Lymphoma
  • Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 09 Nov 2019 Efficacy and adverse events data from a phase II trial in Malignant melanoma presented at the 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC-2019)
  • 08 Nov 2019 Safety and efficacy data from a phase Ib trial in Malignant melanoma presented at the 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC-2019)
  • 02 Oct 2019 Phase-I/II clinical trials in Squamous cell cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA, Australia, Canada, Canada, France, Japan, Japan, Poland, Taiwan, Taiwan, United Kingdom (Parenteral) (NCT02554812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top